Advanced search
1 file | 2.43 MB

Therapeutic bispecific antibody formats : a patent applications review (1994-2017)

Author
Organization
Abstract
Introduction: Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications such as retargeting cellular immunity towards tumor cells. About 23 bispecific antibody platforms have therefore been developed, generating about 62 molecules which are currently being evaluated for potential treatment of a variety of indications, such as cancer and inflammatory diseases, among which three molecules were approved. This class of drugs will represent a multi-million-dollar market over the coming years. Many companies have consequently invested in the development of bispecific antibody platforms, creating an important patent activity in this field. Areas covered: The present review gives an overview of the patent literature over the period 1994-2017 of different immunoglobulin gamma-based bispecific antibody platforms and the molecules approved or in clinical trials. Expert opinion: Bispecific antibodies are progressively accepted as potentially superior therapeutic molecules in a broad range of diseases. This frantic activity creates a maze of hundreds of patents that pose considerable legal risks for both newcomers and established companies. It can consecutively be anticipated that the number of patent conflicts will increase. Nevertheless, it can be expected that patents related to the use of a bispecific antibody will have tremendous commercial value.
Keywords
VARIABLE-DOMAIN IMMUNOGLOBULIN, FAB-ARM EXCHANGE, T-CELLS, CLINICAL, DEVELOPMENT, ANTIGEN-BINDING, IGG ANTIBODIES, PROSTATE-CANCER, HEMOPHILIA-A, SOLID TUMORS, IN-VIVO, Bispecific antibody, BiTE, cancer, CrossMAb, immunoglobulin gamma, inflammatory disease, Knobs-into-Holes, nanobody, Triomab quadroma

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.43 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Godar, Marie, Hans de Haard, Christophe Blanchetot, and Jacobus Rasser. 2018. “Therapeutic Bispecific Antibody Formats : a Patent Applications Review (1994-2017).” Expert Opinion on Therapeutic Patents 28 (3): 251–276.
APA
Godar, M., de Haard, H., Blanchetot, C., & Rasser, J. (2018). Therapeutic bispecific antibody formats : a patent applications review (1994-2017). EXPERT OPINION ON THERAPEUTIC PATENTS, 28(3), 251–276.
Vancouver
1.
Godar M, de Haard H, Blanchetot C, Rasser J. Therapeutic bispecific antibody formats : a patent applications review (1994-2017). EXPERT OPINION ON THERAPEUTIC PATENTS. 2018;28(3):251–76.
MLA
Godar, Marie, Hans de Haard, Christophe Blanchetot, et al. “Therapeutic Bispecific Antibody Formats : a Patent Applications Review (1994-2017).” EXPERT OPINION ON THERAPEUTIC PATENTS 28.3 (2018): 251–276. Print.
@article{8556708,
  abstract     = {Introduction: Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications such as retargeting cellular immunity towards tumor cells. About 23 bispecific antibody platforms have therefore been developed, generating about 62 molecules which are currently being evaluated for potential treatment of a variety of indications, such as cancer and inflammatory diseases, among which three molecules were approved. This class of drugs will represent a multi-million-dollar market over the coming years. Many companies have consequently invested in the development of bispecific antibody platforms, creating an important patent activity in this field. 
Areas covered: The present review gives an overview of the patent literature over the period 1994-2017 of different immunoglobulin gamma-based bispecific antibody platforms and the molecules approved or in clinical trials. 
Expert opinion: Bispecific antibodies are progressively accepted as potentially superior therapeutic molecules in a broad range of diseases. This frantic activity creates a maze of hundreds of patents that pose considerable legal risks for both newcomers and established companies. It can consecutively be anticipated that the number of patent conflicts will increase. Nevertheless, it can be expected that patents related to the use of a bispecific antibody will have tremendous commercial value.},
  author       = {Godar, Marie and de Haard, Hans and Blanchetot, Christophe and Rasser, Jacobus},
  issn         = {1354-3776},
  journal      = {EXPERT OPINION ON THERAPEUTIC PATENTS},
  keyword      = {VARIABLE-DOMAIN IMMUNOGLOBULIN,FAB-ARM EXCHANGE,T-CELLS,CLINICAL,DEVELOPMENT,ANTIGEN-BINDING,IGG ANTIBODIES,PROSTATE-CANCER,HEMOPHILIA-A,SOLID TUMORS,IN-VIVO,Bispecific antibody,BiTE,cancer,CrossMAb,immunoglobulin gamma,inflammatory disease,Knobs-into-Holes,nanobody,Triomab quadroma},
  language     = {eng},
  number       = {3},
  pages        = {251--276},
  title        = {Therapeutic bispecific antibody formats : a patent applications review (1994-2017)},
  url          = {http://dx.doi.org/10.1080/13543776.2018.1428307},
  volume       = {28},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: